Profile data is unavailable for this security.
About the company
Themis Medicare Limited is a research-based pharmaceutical company, which is engaged in the manufacturing of pharmaceutical products, especially in formulation and active pharmaceutical ingredients (API) activity. The Company operates through one segment: Pharmaceuticals. The Company manufactures therapeutic pharma products, differential healthcare products, and APIs based in India. The Company specializes in manufacturing a range of products for application areas like pain management, critical care and anti-infectives. Its analgesic and anti-inflammatory products include Aquadol Tpm Gel, Etojet 90 10'S, Etojet 120 10'S, Etojet Mr Tablets 10'S, Etojet XP Gel, Themidol-P Tab 10's, Dhoom, Aquadol inj, Dyloaqua inj, Joydol -P, Joydol -SP, Joydol -TH, and Nimujet Gel. Its Analgesics products include Anemol, Tazowin, Themidol, Themidol. Its Anesthesia products include Bupicaine 0.25%, Ketmin 2 Vial, Ketmin 5, Ropicaine 2, Themicaine 2%, and more.
- Revenue in INR (TTM)3.37bn
- Net income in INR-174.06m
- Incorporated1969
- Employees1.76k
- LocationThemis Medicare Ltd11/12 Udyog Nagar, S V Road, Goregaon (West)MUMBAI 400104IndiaIND
- Phone+91 2 267607080
- Fax+91 2 228746621
- Websitehttps://www.themismedicare.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kilitch Drugs (India) Ltd | 2.07bn | 264.30m | 5.55bn | 187.00 | 20.00 | -- | 19.91 | 2.68 | 15.87 | 15.87 | 123.46 | -- | -- | -- | -- | 11,074,770.00 | -- | 5.16 | -- | 7.38 | 35.29 | 35.37 | 12.18 | 8.41 | -- | 4.54 | -- | 0.00 | 28.47 | 30.05 | 82.86 | 99.64 | 34.88 | -- |
| Anlon Healthcare Ltd | 1.70bn | 346.64m | 5.93bn | 101.00 | 15.13 | -- | 16.15 | 3.49 | 7.37 | 7.37 | 37.66 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 38.31 | -- | 20.39 | -- | -- | 11.05 | -- | -- | 80.65 | -- | 112.46 | -- | -- | -- |
| Kopran Ltd | 6.20bn | 165.43m | 6.12bn | 1.02k | 37.11 | -- | 18.33 | 0.9868 | 3.41 | 3.41 | 128.28 | -- | -- | -- | -- | 6,052,426.00 | -- | 7.85 | -- | 11.25 | 34.20 | 32.04 | 2.67 | 8.66 | -- | 2.39 | -- | 29.60 | 2.44 | 11.86 | -24.34 | 12.90 | 33.20 | -- |
| Fabtech Technologies Ltd | 3.87bn | 313.94m | 6.56bn | -- | 14.94 | -- | 18.21 | 1.70 | 9.88 | 9.88 | 115.92 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 44.01 | -- | 8.11 | -- | -- | -- | -- | -- | 44.46 | -- | 70.67 | -- | -- | -- |
| Remus Pharmaceuticals Ltd | 7.48bn | 325.59m | 7.16bn | 68.00 | 19.52 | 2.33 | 16.27 | 0.9571 | 31.11 | 31.11 | 701.20 | 260.51 | 1.89 | 9.07 | 7.21 | 109,981,700.00 | 10.44 | 14.37 | 18.44 | 28.60 | 13.01 | 19.39 | 5.51 | 8.39 | 1.07 | 35.59 | 0.0452 | 3.59 | 191.93 | 120.44 | 34.98 | 104.56 | 48.07 | -- |
| Sigachi Industries Ltd | 4.84bn | -762.02m | 7.57bn | 1.10k | -- | -- | -- | 1.56 | -1.97 | -1.97 | 14.66 | -- | -- | -- | -- | 4,421,398.00 | -- | 12.29 | -- | 16.21 | 50.57 | 51.93 | -15.34 | 14.80 | -- | 3.73 | -- | 4.23 | 22.38 | 28.55 | 21.66 | 27.91 | 48.87 | -- |
| Themis Medicare Ltd | 3.37bn | -174.06m | 7.61bn | 1.76k | -- | -- | -- | 2.26 | -1.89 | -1.89 | 36.52 | -- | -- | -- | -- | 1,917,083.00 | -- | 10.17 | -- | 14.38 | 62.56 | 60.61 | -5.16 | 13.52 | -- | -3.71 | -- | 9.36 | 6.22 | 15.00 | -31.46 | 3.78 | 21.58 | 23.36 |
| Anuh Pharma Ltd | 7.68bn | 418.22m | 7.75bn | 295.00 | 18.52 | -- | 14.63 | 1.01 | 4.17 | 4.17 | 76.65 | -- | -- | -- | -- | 26,023,040.00 | -- | 10.41 | -- | 17.00 | 22.25 | 23.95 | 5.45 | 7.35 | -- | 116.27 | -- | 26.59 | 2.24 | 16.60 | -21.16 | 27.05 | -10.78 | 16.89 |
| Accent Microcell Ltd | 2.78bn | 346.64m | 8.29bn | 192.00 | 22.69 | 3.32 | 21.31 | 2.98 | 15.24 | 15.24 | 122.20 | 104.07 | 1.12 | 4.14 | 5.32 | 14,474,330.00 | 13.99 | -- | 15.95 | -- | 39.96 | -- | 12.47 | -- | 3.01 | 76.48 | 0.0046 | -- | 7.77 | -- | 9.60 | -- | -- | -- |
| Venus Remedies Ltd | 7.00bn | 762.95m | 8.71bn | 1.30k | 11.41 | -- | 8.72 | 1.24 | 57.10 | 57.10 | 523.77 | -- | -- | -- | -- | 5,391,957.00 | -- | 6.67 | -- | 8.08 | 47.02 | 37.62 | 10.90 | 6.87 | -- | 1,849.19 | -- | -- | 7.72 | 13.81 | 59.05 | -- | 18.36 | -- |
| Wanbury Ltd | 6.58bn | 646.86m | 8.85bn | 1.38k | 13.24 | -- | 11.18 | 1.35 | 19.13 | 19.13 | 194.16 | -- | -- | -- | -- | 4,758,967.00 | -- | 8.87 | -- | 101.40 | 55.07 | 41.82 | 9.84 | 5.62 | -- | 2.97 | -- | -- | 4.15 | 10.29 | -45.44 | -13.88 | 44.32 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 30 Nov 2025 | 42.96k | 0.05% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 7.28k | 0.01% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Jan 2026 | 927.00 | 0.00% |
| Bandhan AMC Ltd.as of 31 Jan 2026 | 363.00 | 0.00% |
| DFA Australia Ltd.as of 30 Nov 2025 | 182.00 | 0.00% |
